TY - JOUR
T1 - FGF-23 and cardiovascular disease
T2 - Review of literature
AU - Batra, Jasveen
AU - Buttar, Rupinder Singh
AU - Kaur, Pardeep
AU - Kreimerman, Jacqueline
AU - Melamed, Michal L.
N1 - Publisher Copyright:
© 2016 Wolters Kluwer Health, Inc. All rights reserved.
PY - 2016/10/1
Y1 - 2016/10/1
N2 - Purpose of review This review examines associations between fibroblast growth factor 23 (FGF-23) and cardiovascular disease. Recent findings FGF-23 is a hormone produced by osteocytes and osteoblasts that aids with phosphate excretion by the kidney and acts as a negative feedback regulator for activated vitamin D synthesis. Recent studies have found associations between elevated FGF-23 levels and a number of cardiovascular diseases, including hypertension, left ventricular hypertrophy, endothelial dysfunction, cardiovascular events and mortality. Conclusion Recent studies have explored the possible effects of FGF-23 on the cardiovascular system. In animal and observational human studies, there is a link between elevated FGF-23 levels and multiple cardiovascular outcomes, including hypertension, left ventricular hypertrophy and cardiovascular events and mortality. Further studies are required to evaluate whether decreasing FGF-23 levels improves cardiovascular outcomes.
AB - Purpose of review This review examines associations between fibroblast growth factor 23 (FGF-23) and cardiovascular disease. Recent findings FGF-23 is a hormone produced by osteocytes and osteoblasts that aids with phosphate excretion by the kidney and acts as a negative feedback regulator for activated vitamin D synthesis. Recent studies have found associations between elevated FGF-23 levels and a number of cardiovascular diseases, including hypertension, left ventricular hypertrophy, endothelial dysfunction, cardiovascular events and mortality. Conclusion Recent studies have explored the possible effects of FGF-23 on the cardiovascular system. In animal and observational human studies, there is a link between elevated FGF-23 levels and multiple cardiovascular outcomes, including hypertension, left ventricular hypertrophy and cardiovascular events and mortality. Further studies are required to evaluate whether decreasing FGF-23 levels improves cardiovascular outcomes.
KW - Cardiovascular disease
KW - Chronic kidney disease
KW - Fibroblast growth factor 23
KW - Phosphorus
KW - Vitamin D
UR - http://www.scopus.com/inward/record.url?scp=84988578969&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84988578969&partnerID=8YFLogxK
U2 - 10.1097/MED.0000000000000294
DO - 10.1097/MED.0000000000000294
M3 - Review article
C2 - 27652999
AN - SCOPUS:84988578969
SN - 1752-296X
VL - 23
SP - 423
EP - 429
JO - Current Opinion in Endocrinology, Diabetes and Obesity
JF - Current Opinion in Endocrinology, Diabetes and Obesity
IS - 6
ER -
